Q1 2024 Mendus AB (publ) Earnings Call Transcript
()-
Good afternoon, everyone, and thanks for participating in the Mendus Q1 report of 2024. As a listed company, please pay attention to our disclaimer.
To start with Q1, we made significant progress, and we were proud to present a progress together with our business partners ALLG and NorthX Biologics. ALLG is our Australian partner, the Australasian Leukemia Lymphoma Group, with who we are involved in the AMLM22-CADENCE trial. And NorthX Biologics is a manufacturing organization based here in Sweden, who are our partner for large-scale manufacturing of our lead product, vididencel.
We also received in the first quarter ethics committee approval to allow for the start of the AMLM22-CADENCE trial which is currently ongoing. And we have progress in our NK cell program, which we presented at Innate Killer Cell Summit which is a leading conference on that specific topic of NK cell therapies.
We're very happy to announce that our major shareholders as well as management and eligible Board members
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
